CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:The role of immune reconstitution in relapse after allogeneic hematopoietic stem cell transplantation.
The role of immune reconstitution in relapse after allogeneic hematopoietic stem cell transplantation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
移植后的免疫重建在预防复发方面具有巨大潜力,并可能预测疾病复发和预后。高维细胞术、多组学和 T 细胞受体库分析有助于更全面、更详细地理解移植后免疫系统的动态变化,并有助于识别与成功免疫重建或并发症风险增加相关的罕见免疫细胞亚群或潜在生物标志物。增强免疫系统的策略,如过继性免疫治疗和基于细胞因子的治疗,在减少移植后白血病复发方面具有巨大潜力。未来的研究方向应集中于完善这些疗法的患者选择,实施适当且及时的治疗,研究联合方案以最大化治疗结局,并在实现强效的移植物抗白血病(GVL)效应的同时尽量减少移植物抗宿主病(GVHD),以获得最佳结果。
干细胞移植后白血病复发仍是长期缓解的重大障碍。移植后及时且平衡的免疫恢复对于预防白血病复发至关重要。涵盖领域:在通过PubMed和Web of Science对截至2023年10月的文献进行广泛检索后,我们概述了免疫重建的动态及其在控制白血病复发中的作用。我们还讨论了在异基因造血干细胞移植后促进免疫重建和减少疾病复发的策略。
INTRODUCTION: Leukemia relapse following stem cell transplantation remains a significant barrier to long-term remission. Timely and balanced immune recovery after transplantation is crucial for preventing leukemia relapse. AREAS COVERED: After an extensive literature search of PubMed and Web of Science through October 2023, we provide an overview of the dynamics of immune reconstitution and its role in controlling leukemia relapse.
We also discuss strategies to promote immune reconstitution and reduce disease recurrence following allogeneic hematopoietic stem cell transplantation. EXPERT OPINION: Immune reconstitution after transplantation has substantial potential to prevent relapse and might predict disease recurrence and prognosis. High dimensional cytometry, multi-omics, and T cell repertoire analysis allow for a more comprehensive and detailed understanding of the immune system's dynamics post-transplantation, and contribute to the identification of rare immune cell subsets or potential biomarkers associated with successful immune reconstitution or increased risk of complications.
Strategies to enhance the immune system, such as adoptive immunotherapy and cytokine-based therapy, have great potential for reducing leukemia relapse after transplantation. Future research directions should focus on refining patient selection for these therapies, implementing appropriate and timely treatment, investigating combination approaches to maximize therapeutic outcomes, and achieving a robust graft-versus-leukemia (GVL) effect while minimizing graft-versus-host disease (GVHD) for optimal results.
MEMBER ACCOUNT
登录成功会直接打开下一页。